Why is glutathione, rather than cysteine, the major cellular thiol? Our new work by @ToshiNakamura51 suggests unlike other amino acids, excess cysteine is intrinsically toxic to mammalian cells via mitochondrial iron accumulation. @RockefellerUnivnature.com/articles/s42255-0…
Moderna/Merck just ran a 1,137-patient Phase 3 trial where every single dose was unique to that patient's tumor. It worked.
The pipeline: surgical resection → whole exome + RNA sequencing → ML neoantigen ranking → mRNA encoding up to 34 patient-specific targets → manufactured and shipped in 8 weeks. One drug, different sequence for every patient.
The ML step is worth to note: the algorithm ingests WES + RNA-seq to identify somatic mutations, then predicts which of those will actually be immunogenic, ie, displayed on tumor cell surface and trigger a T-cell response. It's designed to keep learning from accumulated clinical and immunogenicity data across patients, not just per-patient.
INTerpath-001 (Stage IIB-IV resected melanoma, 2:1 randomized): combination with pembrolizumab beat Keytruda alone on both primary (RFS) and key secondary (DMFS) at interim. Phase 2b at ASCO 2026 showed 49% reduction in recurrence/death, 59% in distant metastasis/death at 5 years. Phase 3 confirmed both.
What this validates:
— tumor-specific neoantigen prediction by ML works in a blinded trial at scale
— 8-week personalized mRNA manufacturing is operationally real
— effect is additive on PD-1 blockade, not redundant
This is first positive Ph3 for individualized neoantigen therapy. First positive Ph3 for any mRNA cancer therapeutic.
What a great time to live in!! This is the best time for AI & biotech!
Moderna and @Merck today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected Stage IIB-IV melanoma.
Read more:
Our new work by @shanshanliu1218 and @gadmark addresses a fundamental question: how does ER maintain its unique oxidizing environment, while rest of the cell is reducing? Here, we identify SLC33A1 as the major ER GSSG exporter in mammalian cells. nature.com/articles/s41556-0…
Our new work by @shanshanliu1218 and @gadmark addresses a fundamental question: how does ER maintain its unique oxidizing environment, while rest of the cell is reducing? Here, we identify SLC33A1 as the major ER GSSG exporter in mammalian cells. nature.com/articles/s41556-0…
In @NatureCellBio: @KivancBirsoy's lab has discovered that the antioxidant glutathione plays a vital role in maintaining smooth operations of a protein-producing hub in the cell called the endoplasmic reticulum by acting as a protein “proofreader.”
🔗: bit.ly/3Ow8lxM
Check out this impressive work and #tweetorial from @gadmark and @shanshanliu1218! If you’re interested in organellar metabolism and metabolite transport, this is a landmark paper on ER redox metabolism and transport👇
Was an honor to contribute to this tremendous study co-led by the brilliant duo of @gadmark and @shanshanliu1218. Check out the thread below to learn more about how SLC33A1 works to maintain ER redox balance!
Loss of SLC33A1 shifts PDIs toward oxidized states, triggers ER stress, and creates dependency on ERAD. Disease variants linked to Huppke-Brendel syndrome impair GSSG export. This work connects ER redox biology to neurodegeneration and cancer. 8/9
Mutagenesis confirmed the structure. Individual Y225A or Y418A mutations partially impair transport, but the double mutant (2YA) fully phenocopies knockout — no GSSG clearance, full ER stress, no rescue from GSH overload lethality. 7/9
To understand GSSG dynamics in the binding site, we ran 3.4 microseconds of MD simulations. Thanks to @BelayViktor for leading this analysis. The simulations confirmed the extended binding pose and identified key contact residues. 6/9
We solved the cryo-EM structure of GSSG-bound SLC33A1. GSSG sits in an extended conformation deep in the central cavity, coordinated by aromatic residues. No strong ionic interactions — shape and aromaticity do the work. 5/9
We directly confirmed transport by reconstituting purified SLC33A1 into liposomes. Radiolabeled GSSG accumulated in a time-dependent manner in SLC33A1-containing liposomes but not in protein-free vesicles. SLC33A1 is a bona fide GSSG transporter. 4/9